1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jiangsu Atom Bioscience And Pharmaceutical Co. Ltd. has 1 pending office action. This action is assigned to 1 distinct examiner. The matter is located within 1 distinct art unit, showing a focused and limited pending portfolio at this time.
The busiest examiner for this company is KOSACK, JOSEPH R. This examiner is responsible for 1 pending office action. With only 1 action pending in a single art unit, the entire prosecution effort for the company is concentrated under this 1 individual. Practitioners should focus on the specific requirements and feedback of this examiner to advance the application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSACK, JOSEPH R | 1 | 74.8% | -6.1% |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18765174 | URAT1 INHIBITOR AND USE THEREOF | KOSACK, JOSEPH R | 3991 | §102§112DP | Non-Final OA | — | Pending | Jul 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJiangsu Atom Bioscience And Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joseph R Kosack has the most, with 1 of Jiangsu Atom Bioscience And Pharmaceutical Co. Ltd.'s pending office actions.
